Cargando…

Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database

INTRODUCTION: Real-world data on the epidemiology and economic burden of atopic dermatitis (AD) are limited. Here we describe the epidemiology and economic burden of AD using electronic healthcare data from Israel. METHODS: A retrospective study was performed using the Maccabi Healthcare Services da...

Descripción completa

Detalles Bibliográficos
Autores principales: Weil, Clara, Sugerman, Philip B., Chodick, Gabriel, Liang, Huifang, Wang, Hongwei, Calimlim, Brian M., Dorfman, Ana, Shalev, Varda, Ben Amitai, Dan, Leshem, Yael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329417/
https://www.ncbi.nlm.nih.gov/pubmed/35352308
http://dx.doi.org/10.1007/s12325-022-02120-6
_version_ 1784757915729526784
author Weil, Clara
Sugerman, Philip B.
Chodick, Gabriel
Liang, Huifang
Wang, Hongwei
Calimlim, Brian M.
Dorfman, Ana
Shalev, Varda
Ben Amitai, Dan
Leshem, Yael A.
author_facet Weil, Clara
Sugerman, Philip B.
Chodick, Gabriel
Liang, Huifang
Wang, Hongwei
Calimlim, Brian M.
Dorfman, Ana
Shalev, Varda
Ben Amitai, Dan
Leshem, Yael A.
author_sort Weil, Clara
collection PubMed
description INTRODUCTION: Real-world data on the epidemiology and economic burden of atopic dermatitis (AD) are limited. Here we describe the epidemiology and economic burden of AD using electronic healthcare data from Israel. METHODS: A retrospective study was performed using the Maccabi Healthcare Services database. AD incidence in 2008–2017 and point prevalence (AD(prev)) on 31 December 2017 were described using diagnosis codes for overall patients, and sex and age subgroups. For AD(prev), severity was defined using recently dispensed treatments for AD. Annual healthcare resource utilization in AD prevalent patients was compared with non-AD matched controls using generalized linear modelling. Direct annual costs were estimated also. RESULTS: AD incidence was 7.0/1000 person-years; overall prevalence was 4.4% (female patients 4.5%, male patients 4.3%; age 0 to less than 6 months, 0.9%; 6 months to less than 12 years, 11.0%; 12 to less than 18 years, 5.8%; 18 years or older, 2.2%). Among AD(prev) (n = 94,483), mild, moderate, and severe AD comprised 57.7%, 36.2%, and 6.1% (adults 43.8%, 46.3%, 9.9%), respectively. Dermatologist and allergist visits and hospitalization rates (at least one) were 40.7%, 6.6%, and 3.8% in 2017. Compared with controls, overall and moderate-to-severe AD were associated with 36% and 52% increases in annual per-person costs (incremental costs $126 and $190). CONCLUSIONS: AD epidemiology in Israel is comparable with other real-world database studies. AD imposes an economic burden that increases with disease severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02120-6.
format Online
Article
Text
id pubmed-9329417
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-93294172022-07-29 Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database Weil, Clara Sugerman, Philip B. Chodick, Gabriel Liang, Huifang Wang, Hongwei Calimlim, Brian M. Dorfman, Ana Shalev, Varda Ben Amitai, Dan Leshem, Yael A. Adv Ther Original Research INTRODUCTION: Real-world data on the epidemiology and economic burden of atopic dermatitis (AD) are limited. Here we describe the epidemiology and economic burden of AD using electronic healthcare data from Israel. METHODS: A retrospective study was performed using the Maccabi Healthcare Services database. AD incidence in 2008–2017 and point prevalence (AD(prev)) on 31 December 2017 were described using diagnosis codes for overall patients, and sex and age subgroups. For AD(prev), severity was defined using recently dispensed treatments for AD. Annual healthcare resource utilization in AD prevalent patients was compared with non-AD matched controls using generalized linear modelling. Direct annual costs were estimated also. RESULTS: AD incidence was 7.0/1000 person-years; overall prevalence was 4.4% (female patients 4.5%, male patients 4.3%; age 0 to less than 6 months, 0.9%; 6 months to less than 12 years, 11.0%; 12 to less than 18 years, 5.8%; 18 years or older, 2.2%). Among AD(prev) (n = 94,483), mild, moderate, and severe AD comprised 57.7%, 36.2%, and 6.1% (adults 43.8%, 46.3%, 9.9%), respectively. Dermatologist and allergist visits and hospitalization rates (at least one) were 40.7%, 6.6%, and 3.8% in 2017. Compared with controls, overall and moderate-to-severe AD were associated with 36% and 52% increases in annual per-person costs (incremental costs $126 and $190). CONCLUSIONS: AD epidemiology in Israel is comparable with other real-world database studies. AD imposes an economic burden that increases with disease severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02120-6. Springer Healthcare 2022-03-29 2022 /pmc/articles/PMC9329417/ /pubmed/35352308 http://dx.doi.org/10.1007/s12325-022-02120-6 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Weil, Clara
Sugerman, Philip B.
Chodick, Gabriel
Liang, Huifang
Wang, Hongwei
Calimlim, Brian M.
Dorfman, Ana
Shalev, Varda
Ben Amitai, Dan
Leshem, Yael A.
Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title_full Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title_fullStr Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title_full_unstemmed Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title_short Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
title_sort epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide israeli healthcare provider database
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329417/
https://www.ncbi.nlm.nih.gov/pubmed/35352308
http://dx.doi.org/10.1007/s12325-022-02120-6
work_keys_str_mv AT weilclara epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT sugermanphilipb epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT chodickgabriel epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT lianghuifang epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT wanghongwei epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT calimlimbrianm epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT dorfmanana epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT shalevvarda epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT benamitaidan epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase
AT leshemyaela epidemiologyandeconomicburdenofatopicdermatitisrealworldretrospectivedatafromalargenationwideisraelihealthcareproviderdatabase